A New Era in Hepatitis C

Andrew J. Muir, MD MHS
Associate Professor of Medicine
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina
Treatment

• Goal of treatment:
  – Clinical trial definition
  – Sustained virologic response
    • HCV RNA negative 6 months after end of treatment
  – What we tell patients…

Cure!
IDEAL study

- 118 U.S. sites
- 3070 patients
  - All genotype 1
- Peginterferon 2a vs. Peg 2b + ribavirin
- Dose Peg 2b
  - standard 1.5 mcg/kg
  - low dose 1.0 mcg/kg
- Funded by Schering-Plough (maker of Peg 2b)

SVR, %

<table>
<thead>
<tr>
<th></th>
<th>Peg 2a</th>
<th>Peg 2b 1.0</th>
<th>Peg 2b 1.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>SVR, %</td>
<td>40.9</td>
<td>38</td>
<td>38.8</td>
</tr>
</tbody>
</table>

McHutchison JG, *NEJM* 2009
IDEAL trial SVR by racial/ethnic group

![Bar graph showing SVR by racial/ethnic group.](image-url)

<table>
<thead>
<tr>
<th>Racial/Ethnic Group</th>
<th>Peg 2a</th>
<th>Peg 2b 1.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whites</td>
<td>44</td>
<td>44</td>
</tr>
<tr>
<td>African Americans</td>
<td>26</td>
<td>23</td>
</tr>
<tr>
<td>Hispanics</td>
<td>44</td>
<td>39</td>
</tr>
<tr>
<td>Asians</td>
<td>50</td>
<td>70</td>
</tr>
</tbody>
</table>

Muir AJ, *J Viral Hepat* 2010
Boceprevir

- NS3*4a protease inhibitor
- SPRINT-2
- Phase 3, RCT study
- 1097 GT 1 patients
  - No prior treatment
  - Separate cohort of African Americans

Poordad F, AASLD 2010
Boceprevir

SVR, %

Poordad F, AASLD 2010
Telaprevir

- NS3*4a protease inhibitor
- ADVANCE trial
- 8-12 weeks triple combination with SOC
  - SOC to complete 24-48 weeks of treatment
- 1088 genotype 1 patients
  - No previous treatment
Telaprevir

![Graph showing SVR% for Caucasian and African American patients with SOC, T8PR, and T12PR treatments]

- Caucasian:
  - SOC: 46%
  - T8PR: 70%
  - T12PR: 75%

- African American:
  - SOC: 23%
  - T8PR: 58%
  - T12PR: 62%

Jacobson IM, AASLD 2010